Treatment Trials

3 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
      Description

      The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.

      Conditions
      Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or FusionAdvanced Solid Tumors With FGFR1 AmplicationAdvanced Solid Tumors With FGFR2 AmplicationAdvanced Solid Tumors With FGFR3 Mutation
      Talk to us
      RECRUITING
      Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
      Description

      Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC

      Conditions
      Low-grade NMIBCFGFR Gene AmplificationFGFR Gene AlterationsFGFR3 Gene AlterationFGFR3 Gene MutationFGFR3 Gene Fusions
      Talk to us
      RECRUITING
      Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations
      Description

      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.

      Conditions
      Locally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaSolid TumorUrothelial CarcinomaSolid Tumor, AdultBladder CancerNon-muscle-invasive Bladder CancerFGFR3 Gene MutationFGFR3 Gene AlterationAdvanced Solid TumorAdvanced Urothelial CarcinomaUrinary Tract CancerUrinary Tract TumorUrinary Tract Carcinoma
      Talk to us